Notably, since TAK inhibition is under drug development for sensitizing chemotherapy in cancer patients and for several inflammation-associated diseases, our current findings are warrant in considering the pros and cons for targeting TAK in disease treatment. Here, CDK9 is linked to glycogen storage disease VI.